STOCKHOLM – The academic-industry interface emerged as a significant topic during discussions on day two of the BIO-Europe Spring meeting. And while one session focused on the perceived failings of academia – particularly Europe's universities and the surrounding innovation ecosystem – a later session on early stage drug development provided a salutary reminder that industry also has plenty of shortcomings to address if the drug development process is to become more efficient.